Safety Outcomes and Infectious Complications Following Yttrium-90 Radioembolization in Patients with Prior Biliary Interventions: A Comprehensive Review

Background: Yttrium-90 radioembolization (Y-90) is an established locoregional therapy for primary and metastatic liver malignancies. Patients with prior biliary intervention may face a higher risk of infectious complications because of altered biliary anatomy and bacterial colonization. Objective: To evaluate the incidence of infectious complications after Y-90 radioembolization in patients with prior biliary intervention. Methods: PubMed, Embase, and Scopus were searched from inception to June 2026, and risk of bias was assessed for each study. Studies were synthesized descriptively, with per-study proportions and crude totals that count overlapping patients once. Results: Eight studies were included: six retrospective cohorts and two case reports. Four cohorts reported per-patient outcomes in 152 patients; one reported only per procedure, and another was a subset of a larger cohort. Hepatobiliary infection (liver abscess or cholangitis) occurred in 12 of 152 patients (7.9%), liver abscess in 10 (6.6%), cholangitis in 5 (3.3%), and sepsis with hepatobiliary infection in 8 (5.3%); 2 patients died of infection (1.3%). Conclusion: Hepatobiliary infection after Y-90 radioembolization in patients with prior biliary intervention appears less frequent than reported after chemoembolization but more frequent than with intact biliary anatomy. Radioembolization may be a reasonable option in this population.

Authors

Institutions

Publication Details

Journal
Current Oncology
Published
2026-11-19
DOI
https://doi.org/10.3390/curroncol33110715
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Safety Outcomes and Infectious Complications Following Yttrium-90 Radioembolization in Patients with Prior Biliary Interventions: A Comprehensive Review

Ahmed Kamel Abdel Aal, John Moody, Abin Sajan, Kirema Garcia-Reyes et al.
Current Oncology
Hepatocellular Carcinoma Treatment and Prognosis
article

Safety Outcomes and Infectious Complications Following Yttrium-90 Radioembolization in Patients with Prior Biliary Interventions: A Comprehensive Review

Ahmed Kamel Abdel Aal, John Moody, Abin Sajan, Kirema Garcia-Reyes, Zachary T. Berman, Tyler Allan Sandow, Venkatesh P. Krishnasamy, Shamar J Young, Kiyon Naser-Tavakolian, Junaid Y. Raja, Tarub S. Mabud, Shams I. Iqbal, Areeb Siddiqui
article en

Abstract

Background: Yttrium-90 radioembolization (Y-90) is an established locoregional therapy for primary and metastatic liver malignancies. Patients with prior biliary intervention may face a higher risk of infectious complications because of altered biliary anatomy and bacterial colonization. Objective: To evaluate the incidence of infectious complications after Y-90 radioembolization in patients with prior biliary intervention. Methods: PubMed, Embase, and Scopus were searched from inception to June 2026, and risk of bias was assessed for each study. Studies were synthesized descriptively, with per-study proportions and crude totals that count overlapping patients once. Results: Eight studies were included: six retrospective cohorts and two case reports. Four cohorts reported per-patient outcomes in 152 patients; one reported only per procedure, and another was a subset of a larger cohort. Hepatobiliary infection (liver abscess or cholangitis) occurred in 12 of 152 patients (7.9%), liver abscess in 10 (6.6%), cholangitis in 5 (3.3%), and sepsis with hepatobiliary infection in 8 (5.3%); 2 patients died of infection (1.3%). Conclusion: Hepatobiliary infection after Y-90 radioembolization in patients with prior biliary intervention appears less frequent than reported after chemoembolization but more frequent than with intact biliary anatomy. Radioembolization may be a reasonable option in this population.

Current OncologyVol. 33(11)
University of North Carolina at Chapel Hill (US), Ochsner Health System (US), Harvard University (US), University of Arizona (US), Johns Hopkins University (US), Columbia University Irving Medical Center (US), Ochsner Medical Center (US), Johns Hopkins Medicine (US), University of Alabama at Birmingham (US), University of California San Diego (US), Massachusetts General Hospital (US), The University of Texas Health Science Center at Houston (US), Icahn School of Medicine at Mount Sinai (US)
Hepatocellular Carcinoma Treatment and Prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon